91 related articles for article (PubMed ID: 14608985)
1. [Guidelines for performing surface antigen analysis on hematopoietic malignant cells (JCCLS H2-p V1.0)].
Japanese Committe for Clinical Laboratory Standards
Rinsho Byori; 2003 Sep; 51(9):910-26. PubMed ID: 14608985
[No Abstract] [Full Text] [Related]
2. [Guidelines for performing surface antigen analysis on peripheral lymphocytes using flow cytometry by Japanese Committee for Clinical Laboratory Standards (JCCLS), Area Committee on Hematology, and Subcommittee on Flow Cytometry].
Rinsho Byori; 1999 Nov; 47(11):1027-38. PubMed ID: 10590680
[No Abstract] [Full Text] [Related]
3. [Flow cytometric analysis of cell surface antigens].
Yoneyama A
Nihon Rinsho; 2010 Jun; 68 Suppl 6():843-6. PubMed ID: 20942202
[No Abstract] [Full Text] [Related]
4. Transfusion medicine illustrated. Detection of mixed-field agglutination due to loss of red cell antigen in hematopoietic malignancy.
Sheppard CA; O'Reilly KC; Schniederjan SD; Hillyer CD; Roback JD
Transfusion; 2006 Sep; 46(9):1463-4. PubMed ID: 16965568
[No Abstract] [Full Text] [Related]
5. [Flow cytometric cell analysis by surface antigen according to CD grouping].
Tsuruda K; Hamasaki N; Matsuno T; Moriuchi T; Atogami S; Kamihira S
Nihon Rinsho; 2010 Jun; 68 Suppl 6():847-54. PubMed ID: 20942203
[No Abstract] [Full Text] [Related]
6. [The immunology laboratory in malignant blood diseases].
López Berges MC; Vidriales B; Ocqueteau M; Orfao A
Sangre (Barc); 1996 Aug; 41(4):281-8. PubMed ID: 8984669
[No Abstract] [Full Text] [Related]
7. [Cell surface marker (CD-phenotype)].
Takeshita A
Nihon Rinsho; 2007 Jan; 65 Suppl 1():293-8. PubMed ID: 17476749
[No Abstract] [Full Text] [Related]
8. [Antibody therapy for hematopoietic malignancies and cell surface antigen testing].
Higashi K
Rinsho Byori; 2014 Apr; 62(4):352-8. PubMed ID: 25022064
[TBL] [Abstract][Full Text] [Related]
9. [Cell surface markers].
Oritani K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():171-5. PubMed ID: 23133947
[No Abstract] [Full Text] [Related]
10. Interpreting flow cytometry for hematologic neoplasms.
Dayton V; Nguyen PL; Jaszcz V
Am J Clin Pathol; 2000 Jul; 114(1):151-3. PubMed ID: 10884812
[No Abstract] [Full Text] [Related]
11. Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from hematologic malignancies is induced by in vitro angiogenic stimuli and is associated with peculiar functional and phenotypic characteristics.
Campioni D; Lanza F; Moretti S; Ferrari L; Cuneo A
Cytotherapy; 2008; 10(1):69-82. PubMed ID: 18202976
[TBL] [Abstract][Full Text] [Related]
12. Diversity amongst various guidelines for immunophenotyping.
Gujral S; Subramanian PG; Dasgupta A
Cytometry A; 2009 Jul; 75(7):560-1. PubMed ID: 19504568
[No Abstract] [Full Text] [Related]
13. [Clinical values of biomarkers in hematopoietic malignancies].
Kawaguchi T; Nosaka K
Gan To Kagaku Ryoho; 2009 Jan; 36(1):26-31. PubMed ID: 19151562
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous tumors as the initial presentation of non-T, non-B, nonmyeloid CD4+ CD56+ hematolymphoid malignancy in an adolescent boy.
Fass J; Tichy EH; Kraus EW; Herrick JL; Ehsan A; Peterson J; Grimwood RE
Pediatr Dermatol; 2005; 22(1):19-22. PubMed ID: 15660891
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotyping of hematological malignancies by laser scanning cytometry.
Clatch RJ
Methods Cell Biol; 2001; 64():313-42. PubMed ID: 11070846
[No Abstract] [Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia.
Wood BL; Arroz M; Barnett D; DiGiuseppe J; Greig B; Kussick SJ; Oldaker T; Shenkin M; Stone E; Wallace P
Cytometry B Clin Cytom; 2007; 72 Suppl 1():S14-22. PubMed ID: 17803189
[TBL] [Abstract][Full Text] [Related]
18. Quantitative identification of blood cell markers in human hematopoietic malignancies with diagnostic and prognostic significance.
Kusenda J
Neoplasma; 2008; 55(5):381-6. PubMed ID: 18665747
[TBL] [Abstract][Full Text] [Related]
19. DRAQ5-based DNA content analysis of hematolymphoid cell subpopulations discriminated by surface antigens and light scatter properties.
Yuan CM; Douglas-Nikitin VK; Ahrens KP; Luchetta GR; Braylan RC; Yang L
Cytometry B Clin Cytom; 2004 Mar; 58(1):47-52. PubMed ID: 14994375
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies.
Medina DJ; Gharibo M; Savage P; Cohler A; Kuriyan M; Balsara B; Anand M; Schaar D; Krimmel T; Saggiomo K; Manago J; Talty L; Dudek L; Grospe S; Rubin A; Strair RK
Leuk Res; 2008 Dec; 32(12):1842-8. PubMed ID: 18614230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
